APT CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Psychiatric Bulletin All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abdelmawla, N.
Right arrow Articles by Mitchell, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Abdelmawla, N.
Right arrow Articles by Mitchell, A. J.
Advances in Psychiatric Treatment (2006) 12: 35-44
© 2006 The Royal College of Psychiatrists

Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms

Nasser Abdelmawla and Alex J. Mitchell

Nasser Abdelmawla is a specialist registrar in psychiatry. He completed his PhD on psychopharmacology and has an interest in drug-induced adverse effects. Alex Mitchell is a consultant in liaison psychiatry at Leicester General Hospital (Department of Liaison Psychiatry, Brandon Mental Health Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK. Tel.: +44 (0116) 2256218; e-mail: alex.mitchell{at}leicspart.nhs.uk) and author of the BMA prize-winning book Neuropsychiatry and Behavioural Neurology Explained. He is interested in the overlap of physical and mental disorders.

Mortality from causes other than suicide is higher than expected in schizophrenia. Cardiovascular causes are most common, accounting for the majority of the 5% of sudden and unexpected deaths. Most cases have no clear explanation on post-mortem examination (‘sudden unexplained deaths’) and are thought to result from fatal arrhythmias. Prospective studies show that people with prolongation of the QT interval beyond 500 ms are at increased risk of serious arrhythmias such as ventricular tachycardia and torsade de pointes. In about 1 in 10 cases, the torsade is fatal. Most antipsychotics prolong the QTc interval in overdose but some prolong it even at therapeutic doses. Droperidol, sertindole and ziprasidone extend the QT interval by an average of 15–35 ms; quetiapine, haloperidol and olanzapine by 5 ms, to 15 ms. There is only an approximate relationship between QT prolongation and risk of sudden death, and the risk related to antipsychotics is thought to increase in people with pre-existing cardiac disease, those taking multiple QT-acting drugs and those taking antipsychotics at high dose for long periods. There is little evidence of an association with route of administration. More data are required to clarify to what extent people with mental health difficulties who die suddenly have pre-existing cardiac disease.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
N. Abdelmawla and A. J. Mitchell
Sudden cardiac death and antipsychotics. Part 2: Monitoring and prevention
Advan. Psychiatr. Treat., March 1, 2006; 12(2): 100 - 109.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Psychiatric Bulletin All RCPsych Journals
Copyright © 2006 The Royal College of Psychiatrists.